Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Nandrolone-phenpropionate | hsa00030 | Pentose phosphate pathway | 3.67E-03 | 3 | P60891, P11413, P37837 | PRPS1, G6PD, TALDO1 | More | | Nandrolone-phenpropionate | hsa00040 | Pentose and glucuronate interconversions | 3.53E-02 | 1 | O60701 | UGDH | More | | Nandrolone-phenpropionate | hsa00052 | Galactose metabolism | 2.91E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Nandrolone-phenpropionate | hsa00100 | Steroid biosynthesis | 4.70E-02 | 1 | P35610 | SOAT1 | More | | Nandrolone-phenpropionate | hsa00480 | Glutathione metabolism | 1.35E-02 | 1 | P11413 | G6PD | More | | Nandrolone-phenpropionate | hsa00500 | Starch and sucrose metabolism | 1.22E-04 | 4 | O43451, P46976, P35557, P06737 | MGAM, GYG1, GCK, PYGL | More | | Nandrolone-phenpropionate | hsa00512 | Mucin type O-glycan biosynthesis | 1.22E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Nandrolone-phenpropionate | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 4.70E-02 | 1 | P35557 | GCK | More | | Nandrolone-phenpropionate | hsa00730 | Thiamine metabolism | 1.53E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Nandrolone-phenpropionate | hsa00830 | Retinol metabolism | 1.08E-02 | 3 | Q9BPW9, O75911, P11712 | DHRS9, DHRS3, CYP2C9 | More | | Nandrolone-phenpropionate | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Nandrolone-phenpropionate | hsa00983 | Drug metabolism - other enzymes | 3.59E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Nandrolone-phenpropionate | hsa01200 | Carbon metabolism | 2.91E-02 | 1 | P11413 | G6PD | More | | Nandrolone-phenpropionate | hsa01230 | Biosynthesis of amino acids | 3.71E-03 | 5 | P60891, Q99707, P05089, P15104, P37837 | PRPS1, MTR, ARG1, GLUL, TALDO1 | More | | Nandrolone-phenpropionate | hsa01240 | Biosynthesis of cofactors | 2.05E-02 | 2 | P36551, O60701 | CPOX, UGDH | More | | Nandrolone-phenpropionate | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Nandrolone-phenpropionate | hsa02010 | ABC transporters | 4.48E-02 | 1 | Q8IZY2 | ABCA7 | More | | Nandrolone-phenpropionate | hsa03008 | Ribosome biogenesis in eukaryotes | 6.93E-04 | 6 | Q9NYH9, O14980, O60832, P78345, Q9BVP2, Q9GZY0 | UTP6, XPO1, DKC1, RPP38, GNL3, NXF2; NXF2B | More | | Nandrolone-phenpropionate | hsa03010 | Ribosome | 1.22E-02 | 2 | P46777, P50914 | RPL5, RPL14 | More | | Nandrolone-phenpropionate | hsa03013 | RNA transport | 1.32E-05 | 14 | O14980, P52298, O14893, P61326, Q9GZY0, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, P23588, Q9Y6A5, Q53GS7 | XPO1, NCBP2, GEMIN2, MAGOH, NXF2; NXF2B, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, EIF4B, TACC3, GLE1 | More | | Nandrolone-phenpropionate | hsa03015 | mRNA surveillance pathway | 9.78E-03 | 6 | O43148, Q16537, P61326, Q9GZY0, P52298, Q53GS7 | RNMT, PPP2R5E, MAGOH, NXF2; NXF2B, NCBP2, GLE1 | More | | Nandrolone-phenpropionate | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Nandrolone-phenpropionate | hsa04060 | Cytokine-cytokine receptor interaction | 3.93E-03 | 14 | P27930, P14778, P37173, P26842, Q13651, P78552, P25024, P25025, Q9UBD3, P47992, P09341, P80075, P18510, P01730 | IL1R2, IL1R1, TGFBR2, CD27, IL10RA, IL13RA1, CXCR1, CXCR2, XCL2, XCL1, CXCL1, CCL8, IL1RN, CD4 | More | | Nandrolone-phenpropionate | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.04E-02 | 6 | P09341, P25024, P25025, P47992, Q9UBD3, Q13651 | CXCL1, CXCR1, CXCR2, XCL1, XCL2, IL10RA | More | | Nandrolone-phenpropionate | hsa04062 | Chemokine signaling pathway | 6.90E-03 | 10 | P25024, P25025, P09341, P47992, Q9UBD3, P07948, P63218, P50151, Q08881, P49841 | CXCR1, CXCR2, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, ITK, GSK3B | More | | Nandrolone-phenpropionate | hsa04064 | NF-kappa B signaling pathway | 2.10E-02 | 8 | O00463, P14778, Q04759, Q16548, P07948, P06239, P24522, P09341 | TRAF5, IL1R1, PRKCQ, BCL2A1, LYN, LCK, GADD45A, CXCL1 | More | | Nandrolone-phenpropionate | hsa04071 | Sphingolipid signaling pathway | 3.08E-02 | 5 | P17252, Q16537, Q9BX95, P04637, P10415 | PRKCA, PPP2R5E, SGPP1, TP53, BCL2 | More | | Nandrolone-phenpropionate | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Nandrolone-phenpropionate | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Nandrolone-phenpropionate | hsa04145 | Phagosome | 3.27E-04 | 9 | P63261, Q15080, P14598, Q13509, P68371, P05164, O60603, P35443, P13765 | ACTG1, NCF4, NCF1, TUBB3, TUBB2C, MPO, TLR2, THBS4, HLA-DOB | More | | Nandrolone-phenpropionate | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Nandrolone-phenpropionate | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Nandrolone-phenpropionate | hsa04540 | Gap junction | 3.53E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | Nandrolone-phenpropionate | hsa04610 | Complement and coagulation cascades | 1.91E-03 | 1 | P0C0L4 | C4A | More | | Nandrolone-phenpropionate | hsa04613 | Neutrophil extracellular trap formation | 2.89E-02 | 10 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, P14598, Q15080, P21462, P63261 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF1, NCF4, FPR1, ACTG1 | More | | Nandrolone-phenpropionate | hsa04640 | Hematopoietic cell lineage | 3.31E-03 | 9 | P13612, P14778, P27930, P11836, P07766, P09693, P01732, P01730, P13765 | ITGA4, IL1R1, IL1R2, MS4A1, CD3E, CD3G, CD8A, CD4, HLA-DOB | More | | Nandrolone-phenpropionate | hsa04650 | Natural killer cell mediated cytotoxicity | 2.16E-03 | 10 | P16298, P50591, P78314, P06239, O60880, P20963, Q02750, Q13241, P26718, O75015 | PPP3CB, TNFSF10, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, FCGR3B | More | | Nandrolone-phenpropionate | hsa04658 | Th1 and Th2 cell differentiation | 1.64E-06 | 11 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, GATA3, TBX21, HLA-DOB, RUNX3 | More | | Nandrolone-phenpropionate | hsa04659 | Th17 cell differentiation | 2.83E-05 | 11 | Q04759, Q16539, P01730, P06239, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, CD4, LCK, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Nandrolone-phenpropionate | hsa04660 | T cell receptor signaling pathway | 2.18E-05 | 12 | Q04759, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Nandrolone-phenpropionate | hsa04662 | B cell receptor signaling pathway | 2.57E-02 | 5 | P49841, P60033, P07948, P21854, Q8N149 | GSK3B, CD81, LYN, CD72, LILRA2 | More | | Nandrolone-phenpropionate | hsa04666 | Fc gamma R-mediated phagocytosis | 9.96E-03 | 5 | P23528, P49006, P06396, P14598, P17252 | CFL1, MARCKSL1, GSN, NCF1, PRKCA | More | | Nandrolone-phenpropionate | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | Nandrolone-phenpropionate | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Nandrolone-phenpropionate | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Nandrolone-phenpropionate | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | | Nandrolone-phenpropionate | hsa04950 | Maturity onset diabetes of the young | 4.70E-02 | 1 | P35557 | GCK | More | | Nandrolone-phenpropionate | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | | Nandrolone-phenpropionate | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | | Nandrolone-phenpropionate | hsa04972 | Pancreatic secretion | 1.99E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Nandrolone-phenpropionate | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.09E-04 | 5 | Q16539, P09341, P25024, P25025, P07948 | MAPK14, CXCL1, CXCR1, CXCR2, LYN | More | | Nandrolone-phenpropionate | hsa05132 | Salmonella infection | 2.10E-02 | 9 | Q9UJU2, P63261, Q13489, P10415, O60603, Q9BQS8, Q13561, Q13509, P68371 | LEF1, ACTG1, BIRC3, BCL2, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Nandrolone-phenpropionate | hsa05133 | Pertussis | 3.51E-02 | 1 | P0C0L4 | C4A | More | | Nandrolone-phenpropionate | hsa05135 | Yersinia infection | 1.66E-02 | 6 | P13612, P06239, Q16539, P49841, P01730, P01732 | ITGA4, LCK, MAPK14, GSK3B, CD4, CD8A | More | | Nandrolone-phenpropionate | hsa05140 | Leishmaniasis | 4.13E-02 | 5 | P14598, P13765, O60603, P49006, Q15080 | NCF1, HLA-DOB, TLR2, MARCKSL1, NCF4 | More | | Nandrolone-phenpropionate | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | Nandrolone-phenpropionate | hsa05163 | Human cytomegalovirus infection | 8.17E-03 | 9 | P63218, P50151, P49841, P14778, Q13651, P25025, Q16539, O00463, P30101 | GNG5, GNG10, GSK3B, IL1R1, IL10RA, CXCR2, MAPK14, TRAF5, PDIA3 | More | | Nandrolone-phenpropionate | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Nandrolone-phenpropionate | hsa05169 | Epstein-Barr virus infection | 1.68E-03 | 12 | P13765, Q13547, O00463, Q16539, P07948, P30101, Q13761, P24522, P29728, P07766, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, LYN, PDIA3, RUNX3, GADD45A, OAS2, CD3E, CD3G, CD247 | More | | Nandrolone-phenpropionate | hsa05170 | Human immunodeficiency virus 1 infection | 1.09E-03 | 14 | Q02750, P62879, P63218, P50151, P16298, Q05397, O00463, P30101, P01730, Q16539, P07766, P09693, P20963, P20333 | MAP2K1, GNB2, GNG5, GNG10, PPP3CB, PTK2, TRAF5, PDIA3, CD4, MAPK14, CD3E, CD3G, CD247, TNFRSF1B | More | | Nandrolone-phenpropionate | hsa05202 | Transcriptional misregulation in cancer | 6.80E-03 | 12 | Q12778, Q15532, P41732, P14780, P14923, Q13489, O15550, P04637, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, TSPAN7, MMP9, JUP, BIRC3, UTX, TP53, MPO, ELA2, BCL11B, GADD45A | More | | Nandrolone-phenpropionate | hsa05205 | Proteoglycans in cancer | 2.66E-02 | 8 | Q14643, P63261, P04637, P14780, P17252, O60603, Q13635, P08962 | ITPR1, ACTG1, TP53, MMP9, PRKCA, TLR2, PTCH1, CD63 | More | | Nandrolone-phenpropionate | hsa05210 | Colorectal cancer | 3.43E-02 | 2 | Q9UKG1, P37173 | APPL1, TGFBR2 | More | | Nandrolone-phenpropionate | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Nandrolone-phenpropionate | hsa05216 | Thyroid cancer | 3.59E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Nandrolone-phenpropionate | hsa05217 | Basal cell carcinoma | 1.46E-02 | 4 | Q13635, Q9UJU2, P04637, P24522 | PTCH1, LEF1, TP53, GADD45A | More | | Nandrolone-phenpropionate | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Nandrolone-phenpropionate | hsa05230 | Central carbon metabolism in cancer | 1.12E-02 | 1 | P11413 | G6PD | More | | Nandrolone-phenpropionate | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.92E-04 | 8 | O95267, P07766, P20963, P09693, P06239, Q04759, Q16539, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, PRKCQ, MAPK14, CD4 | More | | Nandrolone-phenpropionate | hsa05323 | Rheumatoid arthritis | 3.53E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Nandrolone-phenpropionate | hsa05340 | Primary immunodeficiency | 3.99E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Nandrolone-phenpropionate | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | | Nandrolone-phenpropionate | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | | Nandrolone-phenpropionate | hsa05415 | Diabetic cardiomyopathy | 7.55E-03 | 3 | P30405, P37173, P11413 | PPIF, TGFBR2, G6PD | More | | Nandrolone-phenpropionate | hsa05418 | Fluid shear stress and atherosclerosis | 4.26E-02 | 6 | P14598, P14780, P63261, P04637, P10415, Q92974 | NCF1, MMP9, ACTG1, TP53, BCL2, ARHGEF2 | More | | |